ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA

Clinical trials for ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug targets 'Undruggable' cancer mutations in early human trial

Disease control Recruiting now

This early-stage trial is testing a new drug called WEF-001 in people with advanced cancers that have a specific KRAS mutation. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like pancreatic, colorectal, and lung cancer that have stopped respo…

Matched conditions: ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Auricula Biosciences Inc. • Aim: Disease control

Last updated Apr 01, 2026 19:56 UTC

ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA

Get alerted when new ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA trials appear

New drug targets 'Undruggable' cancer mutations in early human trial